Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ905MR)

This product GTTS-WQ905MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ905MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7685MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ13051MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ14210MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ11171MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ4699MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ13099MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ15615MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ5623MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP791
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW